Kazan Federal University Digital Repository

Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype

Show simple item record

dc.contributor.author Nenasheva N.M.
dc.contributor.author Kurbacheva O.M.
dc.contributor.author Avdeev S.N.
dc.contributor.author Fedosenko S.V.
dc.contributor.author Emelyanov A.V.
dc.contributor.author Belevskiy A.S.
dc.contributor.author Il'Ina N.I.
dc.contributor.author Knyazheskaya N.P.
dc.contributor.author Zyryanov S.K.
dc.contributor.author Ignatova G.L.
dc.contributor.author Demko I.V.
dc.contributor.author Shulzhenko L.V.
dc.contributor.author Leshchenko I.V.
dc.contributor.author Fassakhov R.S.
dc.contributor.author Chernyak B.A.
dc.contributor.author Nedashkovskaya N.G.
dc.contributor.author Bobrikova E.N.
dc.contributor.author Demina D.V.
dc.date.accessioned 2021-02-25T20:35:20Z
dc.date.available 2021-02-25T20:35:20Z
dc.date.issued 2020
dc.identifier.issn 0869-0189
dc.identifier.uri https://dspace.kpfu.ru/xmlui/handle/net/161885
dc.description.abstract © 2020 Medical Education. All rights reserved. Biological therapy of bronchial asthma (BA) is a modern method of treating severe forms of the disease, that are uncontrolled by traditional pharmacotherapeutic approaches. Currently, 5 monoclonal antibody (AT) preparations are registered in the world for the treatment of severe bronchial asthma (SBA) of the T2 endotype (T2-SBA) - antibodies, binding to immunoglobulin (Ig) E (anti-IgE - omalizumab), interleukin antagonists (IL)-5 (anti-IL-5 - mepolizumab, resizumab) and its receptor (anti-IL-5Rα - benralizumab), as well as antibodies, that selectively bind to the IL-4 and -13 receptor (anti-IL-4 /13Rα - dupilumab). The article presents data on the effectiveness of these drugs in relation to the key characteristics of SBA, formulates clinical and laboratory criteria, the study of which in real practice can potentially predict the likelihood of a clinical response to a particular type of biological therapy. An algorithm is proposed for choosing a targeted therapy strategy for patients with SBA, clinically associated with allergies, for patients with severe non-allergic eosinophilic BA and for patients with eosinophilic BA of a combined phenotype.
dc.relation.ispartofseries Pulmonologiya
dc.subject Benralizumab
dc.subject Biological therapy
dc.subject Dupilumab
dc.subject Eosinophilia
dc.subject Mepolizumab
dc.subject Omalizumab
dc.subject Resizumab
dc.subject Severe bronchial asthma
dc.subject T2-endotype
dc.subject Targeted therapy
dc.title Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype
dc.type Article
dc.relation.ispartofseries-issue 2
dc.relation.ispartofseries-volume 30
dc.collection Публикации сотрудников КФУ
dc.relation.startpage 227
dc.source.id SCOPUS08690189-2020-30-2-SID85091496969

Files in this item

This item appears in the following Collection(s)

  • Публикации сотрудников КФУ Scopus [22633]
    Коллекция содержит публикации сотрудников Казанского федерального (до 2010 года Казанского государственного) университета, проиндексированные в БД Scopus, начиная с 1970г.

Show simple item record

Search DSpace

Advanced Search


My Account